NCT06765590招募中不适用
A Randomized, Open-label, Single-dose, Two-period, Two-way Crossover Bioequivalence Study of Paclitaxel for Injection (Albumin Bound) in Subjects With Breast Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- Maximum observed concentration of paclitaxel (Cmax)
研究概览
简要总结
This study was a multicenter, randomized, open, single-dose, two-cycle, two-cross-dosing human bioequivalence trial designed to evaluate the bioequivalence of tested and reference preparations in breast cancer subjects.
详细描述
This study was a multicenter, randomized, open, single-dose, two-cycle, two-cross-dosing human bioequivalence trial designed to evaluate the bioequivalence of tested and reference preparations in breast cancer subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects voluntarily participate in the study and sign the informed consent forms (ICFs);
- •Patients with breast cancer confirmed by histopathology and/or cytology who meet one of the following conditions: ① with metastatic breast cancer that does not respond to combination chemotherapy or recurrent breast cancer within 6 months after adjuvant chemotherapy, and an anthracycline anticancer drug should be used in the previous chemotherapy unless clinically contraindicated; ② investigators determine that subjects are candidates for albumin-bound paclitaxel by reference to the treatment guidelines (NCCN Guidelines and CSCO Guidelines for breast cancer);
- •Aged 18-75 years old (both inclusive), males or females; body mass index (BMI) ≥17 (BMI = weight (kg)/height (m2));
- •The ECOG score is 0-2;
- •The expected survival time is ≥3 months;
- •Subjects have no plans to become pregnant and voluntarily use non-pharmacologic contraception (such as total abstinence, condom, contraceptive ring, vasectomy, etc.) or other highly effective contraceptive methods, and have no plans to donate eggs or sperm throughout the trial and within 6 months after the last dose;
- •Subjects with the laboratory test results as follows: hemoglobin (Hb) ≥80 g/L (no blood transfusion within 14 days), absolute neutrophil count (ANC) ≥1.5 * 109/L, platelet count (PLT) ≥100 * 109/L; alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3 times the upper limit of normal value (for patients without liver metastasis) or ≤5 times the upper limit of normal value (for patients with liver metastasis); total bilirubin (TBIL) ≤1.5 times the upper limit of normal value (for patients without liver metastasis) or ≤3 times the upper limit of normal value (for patients with liver metastasis); serum creatinine clearance ≥60 mL/min [formula: Ccr: (140 - age) * body weight (kg) * 0.85 (if female)/0.818 * Scr (μmol/L)]; international normalized ratio (INR) ≤1.5 times the upper limit of normal value;
- •Subjects are able to communicate well with the investigator and understand and comply with the requirements of the study.
排除标准
- •Subjects with allergic constitution (excluding mild asymptomatic seasonal allergies), or who are known (or suspected) to be allergic to or have a specific reaction to the active ingredient paclitaxel or excipients, albumin;
- •Subjects who have received radiotherapy, chemotherapy, immunotherapy and endocrinotherapy within 4 weeks before the administration of the investigational drug and still respond to the treatment;
- •Subjects who have suffered from serious illness of cardio-cerebral vascular system, lung, liver, kidney, gastrointestinal tract, endocrine system, immune system, skin, musculoskeletal system and nervous system or psychiatric disorders within 3 months before screening and are considered unsuitable for enrollment by the investigator;
- •Subjects who have undergone major surgery or suffered from fracture within 4 weeks prior to screening, or plan to undergo major surgery during the study;
- •Subjects who have received treatment with other investigational drugs within 4 weeks before the study;
- •Subjects who have used substrates, inducers or inhibitors of CYP2C8 or CYP3A4 enzymes (including but not limited to ketoconazole and other imidazole antifungal agents, verapamil, diazepam, quinidine, dexamethasone, cyclosporine, teniposide, etoposide, vincristine, testosterone, 17-α diethylstilbestrol, retinoic acid, quercetin, erythromycin, fluoxetine, gemfibrozil, cimetidine, ritonavir, saquinavir, indinavir, nelfinavir, rifampicin, carbamazepine, phenytoin, efavirenz, nevirapine, etc.) in concomitant medications within 4 weeks prior to the first dose of the investigational drug or fail to suspend medications during the study (except for stable dosing at steady state, i.e. the dosing regimen remains unchanged);
- •Subjects who have consumed special diet (foods that affect the activity of CYP3A4 or CYP2C8 enzyme, such as grapefruit, pomelo, mango, etc.), exercised vigorously or with other factors that may affect drug absorption, distribution, metabolism and excretion within 48 hours before the administration of the investigational drug;
- •Subjects who have received therapy with the granulocyte colony-stimulating factor (G-CSF) within 2 weeks before screening;
- •Subjects with grade 2 or higher sensory neuropathy/peripheral neuropathy at screening;
- •Subjects who have experienced myocardial infarction (within 6 months before the study), severe or unstable angina, and grade III-IV heart failure according to the New York Heart Association (NYHA) Classification, or underwent coronary or peripheral artery bypass grafting;
- •Subjects with poorly controlled hypertension (with the systolic blood pressure of >160 mmHg and/or diastolic blood pressure of >100 mmHg under regular medication);
- •Subjects who have bleeding tendency or are receiving thrombolytic or anticoagulant therapy or have donated or lost more than 400 mL of blood within 3 months before the administration of the investigational drug;
- •Subjects with clinically significant 12-lead ECG abnormalities, who are considered unsuitable for enrollment by the investigator;
- •Subjects with a history of alcohol (drinking more than 14 units of alcohol per week within 6 months prior to the first dose: 1 unit = 285 mL of beer, or 25 mL of spirits, or 100 mL of wine), drug abuse (using narcotic drugs or psychotropic drugs for non-medical purposes) or addiction to drugs, who smoked more than 5 cigarettes per day within 3 months prior to screening, or who could not stop smoking or drinking during the period from signing the ICFs to completing the bioequivalence study;
- •Subjects with positive results of hepatitis B surface antigen (HBsAg), HBV DNA, hepatitis C core antibody (HCV-cAg), HCV RNA, HIV antibody, treponema pallidum antibody, or rapid plasma reagin (RPR) test;
- •Pregnant or lactating women;
- •Other conditions judged inappropriate for participation by the investigator.
研究组 & 干预措施
Test preparation T: Paclitaxel for injection (albumin-bound)
Experimental
干预措施: T, 260 mg/m2, paclitaxel for injection (albumin-bound) (Drug)
Reference Preparation R: Paclitaxel (albumin-bound) for injection (Trade name: ABRAXANE)
Experimental
干预措施: R, 260 mg/m2, paclitaxel for injection (albumin bound). (Drug)
结局指标
主要结局
Maximum observed concentration of paclitaxel (Cmax)
时间窗: Predose: 0 hours; Post-infusion: 0.25 hours, 0.5 hours, 0.75 hours, 1 hour, 1.5 hours, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 36 hours, 48 hours, and 72 hours.
Area under the concentration-time curve from time zero to infinite time of paclitaxel (AUC 0-inf)
时间窗: Predose: 0 hours; Post-infusion: 0.25 hours, 0.5 hours, 0.75 hours, 1 hour, 1.5 hours, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 36 hours, 48 hours, and 72 hours.
Area under the concentration-time curve from time zero to the last time of paclitaxel (AUC 0-t)
时间窗: Predose: 0 hours; Post-infusion: 0.25 hours, 0.5 hours, 0.75 hours, 1 hour, 1.5 hours, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 36 hours, 48 hours, and 72 hours
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
撤回
1 期
To Assess the Bioavailability and Safety of Paclitaxel Injection Concentrate for Suspension in Subjects With Locally Recurrent or Metastatic Breast CancerLocally Recurrent CancerMetastatic Breast CancerNCT04332549Sun Pharma Advanced Research Company Limited
已完成
1 期
Comparing the Pharmacokinetic Profile of LY01612 and CAELYX® in Chinese Subjects With Advanced Breast CancerAdvanced Breast CancerNCT06098599Luye Pharma Group Ltd.48
Unknown
1 期
Bioequivalence Study of Two Formulations of Etoricoxib Tablets 120 mg in Healthy Volunteers Under Fasting ConditionsBioequivalenceNCT04830579Pharmtechnology LLC34
尚未招募
1 期
A Study to Evaluate the Food Effects on Pharmacokinetics of SY-5007 Tablets in Healthy SubjectsHealth SubjectsNCT06325761Shouyao Holdings (Beijing) Co. LTD28
已完成
1 期
Bioequivalence Study of Olaparib Tablets Under Fasting and Fed Conditions in Healthy SubjectsHealthy ParticipantsNCT06360445CSPC Ouyi Pharmaceutical Co., Ltd.102